‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment

BACKGROUND: Treatment with programmed cell death receptor (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors is a promising strategy to lift tumour-induced immune response suppression. However, the current systemic treatment often causes autoimmune side effects. In more than 50% of squamou...

Descripción completa

Detalles Bibliográficos
Autores principales: Rotman, J., Mom, C. H., Jordanova, E. S., de Gruijl, T. D., Kenter, G. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134598/
https://www.ncbi.nlm.nih.gov/pubmed/30208866
http://dx.doi.org/10.1186/s12885-018-4764-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134598/
https://www.ncbi.nlm.nih.gov/pubmed/30208866
http://dx.doi.org/10.1186/s12885-018-4764-0

Ejemplares similares